Skip to main content
Top
Published in: Pediatric Drugs 2/2014

01-04-2014 | Current Opinion

Antidepressant Drugs and the Risk of Suicide in Children and Adolescents

Authors: Göran Isacsson, Charles L. Rich

Published in: Pediatric Drugs | Issue 2/2014

Login to get access

Abstract

Government agencies have issued warnings about the use of antidepressant medications in children, adolescents, and young adults since 2003. The statements warn that such medications may cause de novo ‘suicidality’ in some people. This review explores the data on the treatment of depression that led to these warnings and subsequent data that are relevant to the warnings. It also addresses the effectiveness of antidepressant treatment in general and the relationship of suicide rates to antidepressant treatment. It concludes that the decisions for the ‘black box’ warnings were based on biased data and invalid assumptions. Furthermore, the decisions were unsupported by the observational data regarding suicide in young people that existed in 2003. The following recommendations would seem to follow from these observations. First, drug authorities should re-evaluate the basis for their imposed warnings on antidepressant medicines, and analyze the actual public health consequences the warnings have had. In the absence of substantial evidence supporting the warnings, they should be removed. Second, physicians and other providers with prescription privileges should continue to be educated regarding the importance of aggressively treating depression in young people, using antidepressants when indicated. Third, physicians and other professionals who treat depressed young people must always be aware of the risk of suicide (albeit quite low) and observe them closely for any signs of increased risk of suicide. This is necessary regardless of the type of treatment being provided.
Literature
1.
go back to reference Mann J, Emslie G, Baldessarini R, et al. ACNP task force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31:473–92.PubMedCrossRef Mann J, Emslie G, Baldessarini R, et al. ACNP task force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31:473–92.PubMedCrossRef
2.
go back to reference Busch SH, Frank RG, Leslie DL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv. 2010;61:11–6.PubMedCentralPubMed Busch SH, Frank RG, Leslie DL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? Psychiatr Serv. 2010;61:11–6.PubMedCentralPubMed
3.
go back to reference Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand. 1992;85:444–8.PubMedCrossRef Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr Scand. 1992;85:444–8.PubMedCrossRef
4.
5.
go back to reference Isacsson G, Holmgren A, Osby U, Ahlner J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995–2005. Acta Psychiatr Scand. 2009;120:37–44.PubMedCrossRef Isacsson G, Holmgren A, Osby U, Ahlner J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995–2005. Acta Psychiatr Scand. 2009;120:37–44.PubMedCrossRef
6.
go back to reference Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41–7.PubMedCrossRef Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163:41–7.PubMedCrossRef
7.
go back to reference Busch S, Golberstein E, Meara E. The FDA and ABCS: The unintended consequences of antidepressant warning on human capital. NBER Working Paper Series. 2011. p. 1–48. Busch S, Golberstein E, Meara E. The FDA and ABCS: The unintended consequences of antidepressant warning on human capital. NBER Working Paper Series. 2011. p. 1–48.
8.
go back to reference Brent DA. Antidepressants and pediatric depression—the risk of doing nothing. N Engl J Med. 2004;14(351):1598–601. Brent DA. Antidepressants and pediatric depression—the risk of doing nothing. N Engl J Med. 2004;14(351):1598–601.
9.
go back to reference Jellinek MS, Snyder JB. Depression and suicide in children and adolescents. Pediatr Rev/Am Acad Pediatr. 1998;19:255–64.CrossRef Jellinek MS, Snyder JB. Depression and suicide in children and adolescents. Pediatr Rev/Am Acad Pediatr. 1998;19:255–64.CrossRef
10.
go back to reference Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980–9.PubMedCentralPubMedCrossRef Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010;49:980–9.PubMedCentralPubMedCrossRef
11.
go back to reference Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;24(363):1341–5.CrossRef Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;24(363):1341–5.CrossRef
12.
go back to reference von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26:311–5.CrossRef von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol. 2006;26:311–5.CrossRef
13.
go back to reference Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280–8.PubMedCrossRef Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280–8.PubMedCrossRef
14.
go back to reference Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand. 2007;115:184–95.PubMedCrossRef Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs? Acta Psychiatr Scand. 2007;115:184–95.PubMedCrossRef
15.
go back to reference March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;18(292):807–20. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA. 2004;18(292):807–20.
16.
go back to reference Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031–7.PubMedCrossRef Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031–7.PubMedCrossRef
17.
go back to reference Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205–15.PubMedCrossRef Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002;41:1205–15.PubMedCrossRef
18.
go back to reference Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;5(69):572–9. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;5(69):572–9.
19.
go back to reference Duff G. Safety of Seroxat (paroxetine) in children and adolescents under 18 years—contraindication in the treatment of depressive illness. In: MHRA, editor. Message from professor G Duff, Chairman of Committee on Safety of Medicines; 2003. Duff G. Safety of Seroxat (paroxetine) in children and adolescents under 18 years—contraindication in the treatment of depressive illness. In: MHRA, editor. Message from professor G Duff, Chairman of Committee on Safety of Medicines; 2003.
22.
go back to reference Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry. 2005;17:153–62.PubMedCrossRef Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry. 2005;17:153–62.PubMedCrossRef
23.
go back to reference Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. J Policy Anal Manag. 2005;24:249–72.CrossRef Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. J Policy Anal Manag. 2005;24:249–72.CrossRef
24.
go back to reference Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand. 2005;111:286–90.PubMedCrossRef Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14,857 suicides. Acta Psychiatr Scand. 2005;111:286–90.PubMedCrossRef
26.
go back to reference Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003;60:978–82.PubMedCrossRef Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003;60:978–82.PubMedCrossRef
27.
go back to reference Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;2006(163):1898–904.CrossRef Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006;2006(163):1898–904.CrossRef
28.
go back to reference Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Markham Piper T, Galea S. Antidepressants and youth suicide in New York City, 1999–2002. J Am Acad Child Adolesc Psychiatry. 2006;45:1054–8.PubMedCrossRef Leon AC, Marzuk PM, Tardiff K, Bucciarelli A, Markham Piper T, Galea S. Antidepressants and youth suicide in New York City, 1999–2002. J Am Acad Child Adolesc Psychiatry. 2006;45:1054–8.PubMedCrossRef
29.
go back to reference Moskos M, Olson L, Halbern S, Keller T, Gray D. Utah youth suicide study: psychological autopsy. Suicide Life Threat Behav. 2005;35:536–46.PubMedCrossRef Moskos M, Olson L, Halbern S, Keller T, Gray D. Utah youth suicide study: psychological autopsy. Suicide Life Threat Behav. 2005;35:536–46.PubMedCrossRef
30.
go back to reference Sondergard L, Kvist K, Andersen PK, Kessing LV. Do antidepressants precipitate youth suicide? A nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry. 2006;15:232–40.PubMedCrossRef Sondergard L, Kvist K, Andersen PK, Kessing LV. Do antidepressants precipitate youth suicide? A nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry. 2006;15:232–40.PubMedCrossRef
31.
go back to reference Dudley M, Goldney R, Hadzi-Pavlovic D. Are adolescents dying by suicide taking SSRI antidepressants? A review of observational studies. Australas Psychiatry. 2010;18:242–5.PubMedCrossRef Dudley M, Goldney R, Hadzi-Pavlovic D. Are adolescents dying by suicide taking SSRI antidepressants? A review of observational studies. Australas Psychiatry. 2010;18:242–5.PubMedCrossRef
32.
go back to reference Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164:1356–63.PubMedCrossRef Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164:1356–63.PubMedCrossRef
33.
go back to reference Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance—United States, 2001. J Sch Health. 2002;72:313–28.PubMedCrossRef Grunbaum JA, Kann L, Kinchen SA, et al. Youth risk behavior surveillance—United States, 2001. J Sch Health. 2002;72:313–28.PubMedCrossRef
34.
go back to reference Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials. 2009;6:109–18.PubMedCrossRef Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials. 2009;6:109–18.PubMedCrossRef
35.
go back to reference Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164:884–91.PubMedCrossRef Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry. 2007;164:884–91.PubMedCrossRef
36.
go back to reference Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66:633–9.PubMedCrossRef Libby AM, Orton HD, Valuck RJ. Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry. 2009;66:633–9.PubMedCrossRef
37.
go back to reference Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64:466–72.PubMedCrossRef Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64:466–72.PubMedCrossRef
38.
go back to reference Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94–101.PubMedCrossRef Olfson M, Marcus SC, Druss BG. Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94–101.PubMedCrossRef
39.
go back to reference Tournier M, Greenfield B, Galbaud du Fort G, et al. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res. 2010;179:57–63.PubMedCrossRef Tournier M, Greenfield B, Galbaud du Fort G, et al. Patterns of antidepressant use in Quebec children and adolescents: trends and predictors. Psychiatry Res. 2010;179:57–63.PubMedCrossRef
40.
go back to reference Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents—changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf. 2007;16:1048–53.PubMedCrossRef Dean AJ, Hendy A, McGuire T. Antidepressants in children and adolescents—changes in utilisation after safety warnings. Pharmacoepidemiol Drug Saf. 2007;16:1048–53.PubMedCrossRef
42.
go back to reference Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18 s in the United Kingdom: ecological study. BMJ. 2008;8(336):542–5.CrossRef Wheeler BW, Gunnell D, Metcalfe C, Stephens P, Martin RM. The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18 s in the United Kingdom: ecological study. BMJ. 2008;8(336):542–5.CrossRef
43.
go back to reference Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf Int J Med Toxicol Drug Exp. 2005;28:1151–7.CrossRef Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. Drug Saf Int J Med Toxicol Drug Exp. 2005;28:1151–7.CrossRef
44.
go back to reference Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012;7:e33181.PubMedCentralPubMedCrossRef Wijlaars LP, Nazareth I, Petersen I. Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One. 2012;7:e33181.PubMedCentralPubMedCrossRef
45.
go back to reference Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. Suicide trends among youths aged 10 to 19 years in the United States, 1996–2005. JAMA. 2008;300:1025–6.PubMedCrossRef Bridge JA, Greenhouse JB, Weldon AH, Campo JV, Kelleher KJ. Suicide trends among youths aged 10 to 19 years in the United States, 1996–2005. JAMA. 2008;300:1025–6.PubMedCrossRef
46.
go back to reference Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ. 2008;8(178):1005–11.CrossRef Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J. Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ. 2008;8(178):1005–11.CrossRef
47.
go back to reference Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry. 2009;70:741–7.PubMedCentralPubMedCrossRef Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry. 2009;70:741–7.PubMedCentralPubMedCrossRef
48.
go back to reference Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;9(69):580–7.CrossRef Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;9(69):580–7.CrossRef
49.
go back to reference Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207–10.PubMed Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207–10.PubMed
50.
go back to reference Busch S, Golberstein E, Meara E. The FDA and ABCs: The unintended consequences of antidepressant warnings on human capital. NBER Working Paper Series. 2011. p. 1–48. Busch S, Golberstein E, Meara E. The FDA and ABCs: The unintended consequences of antidepressant warnings on human capital. NBER Working Paper Series. 2011. p. 1–48.
51.
go back to reference Leon AC. The revised black box warning for antidepressants sets a public health experiment in motion. J Clin Psychiatry. 2007;68:1139–41.PubMedCrossRef Leon AC. The revised black box warning for antidepressants sets a public health experiment in motion. J Clin Psychiatry. 2007;68:1139–41.PubMedCrossRef
Metadata
Title
Antidepressant Drugs and the Risk of Suicide in Children and Adolescents
Authors
Göran Isacsson
Charles L. Rich
Publication date
01-04-2014
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 2/2014
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-013-0061-1

Other articles of this Issue 2/2014

Pediatric Drugs 2/2014 Go to the issue